Entecavir: a new treatment option for chronic hepatitis B

Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
Fabien Zoulim

Abstract

Because of the slow kinetics of viral clearance and the spontaneous genetic variability of hepatitis B virus (HBV), antiviral therapy of chronic hepatitis B remains a clinical challenge. Despite the recent development of lamivudine, adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic HBV infection, there is still a major need for new antiviral compounds. Entecavir, a guanosine analog, has been recently approved in US for the therapy of chronic hepatitis B and its registration is expected soon in Europe. Extensive studies have been performed to characterize its antiviral activity in enzymatic and tissue culture models, as well as in animal models of HBV infection. In clinical trails, entecavir administration was associated with a significantly more potent viral suppression compared to lamivudine, and a significant advantage in terms of biochemical and histological improvement compared to lamivudine. Entecavir was tolerated as well as lamivudine in these phase III trials. No case of resistance was detected after two years of therapy in nucleoside naive patients. Treatment of patients with lamivudine failure requires a higher dosage of entecavir and induces a significant decline in viraemia levels. Howev...Continue Reading

References

Jun 6, 1998·Virology·W S MasonA R Jilbert
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·Patricia L MarionRichard J Colonno
Nov 22, 2002·The New England Journal of Medicine·Andreas GeierChristoph G Dietrich
Mar 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ching-Lung LaiLynn Condreay
Dec 4, 2003·Journal of Hepatology·Jean-Pierre VilleneuveFabien Zoulim
Sep 7, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Ching-Lung LaiMaureen W Myers
Sep 17, 2004·The New England Journal of Medicine·Patrick MarcellinUNKNOWN Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group
Oct 8, 2004·The New England Journal of Medicine·Yun-Fan LiawUNKNOWN Cirrhosis Asian Lamivudine Multicentre Study Group
May 26, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marie-Noëlle BrunelleFabien Zoulim
Jul 1, 2005·The New England Journal of Medicine·Stephanos J HadziyannisUNKNOWN Adefovir Dipivoxil 438 Study Group
Jul 1, 2005·The New England Journal of Medicine·George K K LauUNKNOWN Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group

❮ Previous
Next ❯

Citations

Feb 20, 2009·Journal of Gastroenterology and Hepatology·Yoshiyuki SuzukiHiromitsu Kumada
Apr 1, 2009·Clinical Journal of Gastroenterology·Yasuteru KondoTooru Shimosegawa
Sep 4, 2008·Expert Opinion on Emerging Drugs·Erik De Clercq
Jul 3, 2007·Expert Opinion on Emerging Drugs·Fabien Zoulim
Sep 1, 2015·Chemical Reviews·Vedanjali GogineniMark T Hamann
May 24, 2006·Antiviral Research·Fabien Zoulim
Jun 1, 2010·Viruses·Erik De ClercqJohan Neyts
Nov 30, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Fabien Zoulim
Oct 30, 2007·Reviews in Medical Virology·Geoffrey FérirErik De Clercq
Dec 8, 2011·Current Protocols in Nucleic Acid Chemistry·Ravindra K RawalChung K Chu
Jan 28, 2020·Biomacromolecules·Alexandra K AbelMatthew L Becker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.